3.75Open3.75Pre Close0 Volume23 Open Interest39.00Strike Price0.00Turnover0.00%IV2059.09%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry3.75Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.53Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet